Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001415889-25-004199
Filing Date
2025-02-14
Accepted
2025-02-14 17:38:41
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 12699
2 JOINT FILING AGREEMENT ex-99-02142025_100239.htm EX-99.1 4353
  Complete submission text file 0001415889-25-004199.txt   18848
Mailing Address C/O MAPLES CORPORATE SERVICES LIMITED UGLAND HOUSE, P.O. BOX 309 GRAND CAYMAN E9 KY1-1104
Business Address C/O MAPLES CORPORATE SERVICES LIMITED UGLAND HOUSE, P.O. BOX 309 GRAND CAYMAN E9 KY1-1104 345-949-8066
Decheng Capital Global Life Sciences Fund IV, L.P. (Filed by) CIK: 0001834150 (see all company filings)

EIN.: 981568621 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 890 WINTER STREET, SUITE 200 WALTHAM MA 02451
Business Address 890 WINTER STREET, SUITE 200 WALTHAM MA 02451 781-208-2466
Upstream Bio, Inc. (Subject) CIK: 0002022626 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94651 | Film No.: 25631329
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)